Eli Lilly's lepodisiran small interfering RNA therapy Phase 2 clinical results are positive for treating hereditary heart disease
Eli Lilly announced on March 30, 2025, that lepodisiran achieved positive results in the Phase 2 ALPACA clinical study. The therapy significantly reduced levels of the hereditary cardiovascular risk factor Lp(a), with a maximum reduction of 93.9%. The study showed that after receiving different doses of lepodisiran, patients' Lp(a) levels continued to decrease over nearly 18 months, with some patients experiencing effects lasting up to 1.5 years
According to Zhitong Finance APP, on March 30, 2025, Eli Lilly (LLY.US) announced positive results for lepodisiran in Phase 2 clinical trials. Lepodisiran is an investigational small interfering RNA (siRNA) therapy designed to reduce the production of lipoprotein(a) [Lp(a)]. Lp(a) is a risk factor for hereditary heart disease. In the Phase 2 ALPACA study, lepodisiran reduced Lp(a) levels by an average of 93.9% during the period from day 60 to day 180 after treatment at the highest tested dose (400mg), achieving the primary endpoint of the study. Participants receiving lepodisiran at doses of 16mg and 96mg had Lp(a) levels reduced by 40.8% and 75.2%, respectively, during the same time period.
Lepodisiran also achieved several secondary endpoints. In the nearly 18-month study, all assessment time points showed a reduction in Lp(a) levels after a single or double administration of lepodisiran at three tested doses (16mg, 96mg, or 400mg). The study was designed to administer lepodisiran (16mg, 96mg, or 400mg) once at baseline and again at day 180, with an additional group receiving lepodisiran 400mg at baseline and a placebo at day 180. The effects of additional doses of lepodisiran have yet to be determined
